Dr. Anand C. Burman
Co-Founder & Chairman
Dr. Anand Burman is one of India's leading industrialists and Chairman of the Dabur Group, a diversified USD $2.8 billion market capitalization FMCG conglomerate with business in healthcare, personal care and food products. Dr. Burman has an outstanding track record as a healthcare operator in running enterprises and achieving high return exits, and his deal networks penetrate the most senior levels of business and government in Southeast Asia, particularly India.
Dr. Burman also currently serves as Chairman of Dabur India Limited and the Confederation of Indian Industry (CII) National Committee on Biotechnology. In addition, he is a Director for Fresenius Kabi Oncology Ltd., Aviva Life Insurance Co. India Ltd., Dabur Research Foundation, and Hindustan Motors Limited. Dr. Burman is also a member of the Council of Governors at Birkbeck College at the University of London.
He received his Bachelor of Science in Chemistry from the University of Wisconsin, USA, and his Master of Science in Chemistry and Doctorate in Pharmaceutical Chemistry from the University of Kansas, USA.
Mr. Ajay Kumar Vij
Co-Founder & CEO
Ajay Kumar Vij was formerly the CEO of Dabur Pharma, a fully integrated global pharmaceutical company which he successfully built up over 13 years into one of the world's largest specialty oncology groups that operated in 40 countries around the world including USA, Europe, Latin America, and the Asia Pacific region. He was instrumental in selling the company to European healthcare major Fresenius for over USD $360 million in 2008. He has broad exposure to the Asian healthcare sector and has wide experience in identifying promising business opportunities, developing a growth strategy and implementing profitable exits.
Ajay serves as Non-Executive Director in Diwan Chand Medical Services P. Ltd., Dabur Research Foundation, Althea Lifesciences Limited and Famy Care Limited.
Ajay is a member of the Young Presidents' Organization (YPO).
He holds a MBA and Bachelor degree in Science from Punjab University, Chandigarh, India.
Sameer joins the Fund from Nomura Securities where he headed the India team for their Prop book Private Equity division. He has an overall 18 years of investing and operating experience including over 14 years in the Private Equity / Venture Capital space across leading Indian and International platforms like Nomura, IL&FS, Vertex Management and GVFL.
During his PE career, Sameer has invested in and worked closely with a number of companies & entrepreneurs in the Consumer services and Technology sectors in India and South East Asia. He has extensive experience in deal origination, due diligence, deal execution, exits and portfolio management including working with early stage portfolio companies in areas like corporate strategy, business development, M&A and new business initiatives.
Prior to his VC experience, Sameer had operational assignments at two Indian engineering companies viz - Crompton Greaves and DGP Windsor.
Sameer is an Electrical Engineer from the University of Pune, an MBA from SP Jain Institute of Management and Research, and a Chartered Financial Analyst (CFA) from the CFA Institute, US.
Sameer is closely associated with and is on the Investment Committee of Aavishkaar, India's first Social Venture Capital firm. He is also involved with Takshashila an Independent networked think tank on India's strategic affairs
Mr. Shailendra Tandon
Operating Partner & CFO
Shailendra Tandon was formerly the CFO of Dabur Pharma Limited. His experience of over three decades is a rich blend of Business Strategy & Operations, M&A, Corporate Finance and HR in multi-nationals (ICI, Bausch & Lomb and Carrier Aircon) as well as large Indian companies (Indo Rama and Escorts) at leadership level.
He has served as a member of Boards, member of Management Committees, member of Audit Committees, shared responsibility for delivering bottom lines in various businesses and has mentored business management teams. He has served as a member of Boards, Management Committees, Audit Committees, Corporate Director and CFO.
As a well rounded business manager with strong commercial acumen, he has in his previous assignments shared responsibility for delivering bottom lines in various businesses, dealt with board level and corporate issues and has mentored business teams. He has structured complex business transactions including partnerships and JV agreements both domestic and international.
He understands well the psyche of Indian promoters and has experiential knowledge of the working dynamics of multinational companies. His collaborative approach together with unwavering focus on the end objectives, mature judgment and decisive thinking make him an astute dealmaker. He has been the lead negotiator in many situations: with business promoters/ owners and investment bankers for purchase and sale of businesses; with potential and existing JV partners; with project vendors; finance lenders; worker union representative and other business professionals.
He has a proven track record of successful corporate transactions, which includes sale of Fertiliser and Fibers business of ICI in 1994, restructuring of Bausch & Lomb India to segregate Rayban business from the core business in 2000, demerger of the textile business of Indo Rama into a separate company in 2003, sale of Escorts Heart Hospital in 2005 to the Fortis group and sale of Dabur Pharma Limited in 2008 to a European healthcare company, Fresenius Kabi Plc.
He has brought order and organisation to many situations by building cohesive teams and systems orientation. He brings to the table experience of diverse work cultures having worked in different parts of India and experience that has been gained during his extensive travels overseas.
He holds a Bachelor degree in Science from Lucknow University, UP India and is a Chartered Accountant from the Institute of Chartered Accountants of India.
Dr. Sanuj Ravindran
Dr. Sanuj Ravindran joined the Fund in February 2010 from Radius Ventures, a New York-based private equity firm focused on global healthcare and life science investments. As a Principal of Radius, from 2007-2010, Dr. Ravindran invested in and assumed Board roles with Ambit Biosciences, Athersys Inc and Resolvyx Pharmaceuticals, and worked closely with Biostorage Inc. Prior to Radius, Dr. Ravindran was a Director of Burrill & Company, a San Francisco-based healthcare and life science private equity firm, where he founded and led the Burrill India Group. While at Burrill from 2003-2007, Dr. Ravindran also assumed Board roles with diaDexus Inc and Proventys Inc, and played an active role in several other investments, including Endocyte Inc, Pharmasset Inc. and CardioKine Inc. Previously, Dr. Ravindran worked in the Healthcare Investment Banking Group at Merrill Lynch, where he advised on financings, partnering and M&A for a variety of healthcare and life science clients.
A U.S. licensed physician, Dr. Ravindran is Board Certified in Internal Medicine and completed his residency training at Thomas Jefferson University Hospital in Philadelphia. Dr. Ravindran was also a National Cancer Institute Research Fellow at Memorial Sloan Kettering Cancer Centre in New York, and has published research in a variety of clinical disciplines. Currently, Dr. Ravindran is a member of the Society of Kauffman Fellows; serves on the Editorial Board of Biotechnology-Healthcare; is a Senior Scholar with the Jefferson School of Public Health; and is on the Advisory Board of RxMD, a clinical development services firm based in Chennai, India. Dr. Ravindran received a BA with Honours from Northwestern University, a MD from Jefferson Medical College and a MBA from the Kellogg School of Management, where he was a Rothschild Scholar. Dr. Ravindran is also an honorary alumnus of the Indian School of Business in Hyderabad, India.
Dr. Mario Gobbo
Dr. Mario Gobbo was recently Managing Director for Healthcare Capital Markets with Natixis Bleichroeder, a New York investment bank and subsidiary of Natixis, a listed French bank. During the last two years, he sourced IPOs for Jazz Pharmaceuticals and Biodel, follow-on transactions for Natus, Biodel, Orexigen and Vanda, advisory private placement assignments for RXi and Ocimum/Genelogic (ongoing), a fairness opinion for Avax, and obtained a sell-side and a buy-side mandate in the health care industry. He also worked with WuXi, the Chinese CRO, and Guerbet, Ipsen and Cellectis, three French health care companies. Before joining Natixis Bleichroeder, he was in charge of life sciences investments for the International Finance Corporation, the private sector arm of The World Bank. Dr. Gobbo has completed investments in a number of Indian companies and has over 27 years of banking and finance experience of which nine years were spent with Lazard in London. Dr. Gobbo's experience spans pharmaceuticals and biotechnology, as well as energy and telecommunications.
Dr. Gobbo holds a BA with a major in Organic Chemistry from Harvard College, a M.Sc. in Biochemistry from the University of Colorado and an MBA, a Master of Business Economics and a PhD from the Wharton School of the University of Pennsylvania.
Mr. Damien Lim
Senior Investment Advisor
Damien Lim is General Partner and co-founder of Singapore based BioVeda Capital, a Venture fund focused on early stage investments in the life sciences, principally in drug discovery and medical technologies. Amongst the companies which have been funded by BioVeda, three have gone public on NASDAQ, one on the London Stock Exchange, and one was acquired by Pfizer Pharmaceuticals. Previously, Mr. Lim was Director, Investments with Prime Partners, a boutique private equity fund which invested in Southeast Asia and Hong Kong. Mr. Lim was also Executive Director of Vickers Ballas Asset Management, responsible for Southeast Asian and Indian investments, and an Investment Committee member of the New York Life International India Fund, one of the first India focused private equity funds and which was an early investor in Bharti Telecoms.
Mr. Lim currently sits on various boards and is a member of the Proof of Concept grant committee of the National Research Foundation in Singapore. He served for two terms as a Committee member of the Singapore Private Equity and Venture Capital Association. Mr. Lim has a BBA from the University of Houston.
Dr. Preet Pal Thakur
Dr. Preet Pal Thakur is a Vice President with Asian Healthcare Fund. Dr. Preet has more than 10 years of life sciences experience spanning across venture capital/ private equity, investment banking and clinical practice. He was previously with Milestone Religare PE Fund, a $100 Mn fund focused on healthcare and education in India. At Milestone Religare he played a significant role, in particularly, in their healthcare investments amongst other investments.
Earlier in his career, Dr Preet was a part of the Healthcare Investment banking team at J P Morgan India in the equity research arm covering Indian Healthcare and Pharmaceutical companies like Ranbaxy, Glenmark and Cipla etc. for more than 2 years. Prior to that, he practiced medicine for 2 years in Northern India, where his last assignment was with Fortis Hospitals, Chandigarh as a Resident doctor in their Cardiology department.
Dr Preet holds an M.B.A in Finance from IIM Indore and an M.B.B.S from Medical College, Patiala. He is also pursuing his CFA charter from CFA Institute USA.
He is a consummate sports buff and enjoys travelling, reading and listening to music. He was the college cricket team captain during his medicine days.